Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Long-acting amylin analogues for the management of obesity

Research output: Contribution to journalReviewResearchpeer-review

  1. Calcitonin gene-related peptide and pituitary adenylate cyclase-activating polypeptide in migraine treatment

    Research output: Contribution to journalReviewResearchpeer-review

  2. Hashimoto's thyroiditis as a risk factor for thyroid cancer

    Research output: Contribution to journalReviewResearchpeer-review

  3. Gut hormones in the treatment of short-bowel syndrome and intestinal failure

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Updates in weight loss surgery and gastrointestinal peptides

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Beta-hydroxybutyrate suppresses hepatic production of the ghrelin receptor antagonist, LEAP2

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. THERAPY OF ENDOCRINE DISEASE: Amylin and calcitonin - physiology and pharmacology

    Research output: Contribution to journalReviewResearchpeer-review

  3. LEAP2 reduces postprandial glucose excursions and ad libitum food intake in healthy men

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Gastric Aspiration Improves Postprandial Glucose Tolerance Without Causing a Compensatory Increase in Appetite and Food Intake

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

PURPOSE OF REVIEW: To summarize recent developments of long-acting amylin analogues for the treatment of obesity and to outline their mode of action.

RECENT FINDINGS: Amylin is a pancreatic hormone acting to control energy homeostasis and body weight. Activity at the calcitonin and amylin receptors in the area postrema seems to - at least partly - be responsible for these effects of amylin. Both preclinical and early-stage clinical studies investigating long-acting amylin receptor analogues demonstrate beneficial effects on body weight in obesity. Cagrilintide, a novel amylin analogue suitable for once-weekly administration, is in phase II clinical development and has shown promising body weight reducing effects alone and in combination with the glucagon-like peptide 1 receptor agonist semaglutide.

SUMMARY: Long-acting amylin analogues have emerged as a possible pharmacotherapy against obesity, but more studies are needed to support the utility and long-term effects of this strategy in relevant populations.

Original languageEnglish
JournalCurrent Opinion in Endocrinology, Diabetes and Obesity
Volume29
Issue number2
Pages (from-to)183-190
Number of pages8
ISSN1752-296X
DOIs
Publication statusPublished - 1 Apr 2022

Bibliographical note

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

ID: 74076954